{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:52:41Z","timestamp":1792356761770,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T00:00:00Z","timestamp":1264032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Despite widespread use of colchicine, the evidence basis for oral colchicine therapy and dosing in acute gout remains limited. The aim of this trial was to compare low\u2010dose colchicine (abbreviated at 1 hour) and high\u2010dose colchicine (prolonged over 6 hours) with placebo in gout flare, using regimens producing comparable maximum plasma concentrations in healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study compared self\u2010administered low\u2010dose colchicine (1.8 mg total over 1 hour) and high\u2010dose colchicine (4.8 mg total over 6 hours) with placebo. The primary end point was \u226550% pain reduction at 24 hours without rescue medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 184 patients in the intent\u2010to\u2010treat analysis. Responders included 28 of 74 patients (37.8%) in the low\u2010dose group, 17 of 52 patients (32.7%) in the high\u2010dose group, and 9 of 58 patients (15.5%) in the placebo group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005 and\n                      <jats:italic>P<\/jats:italic>\n                      = 0.034, respectively, versus placebo). Rescue medication was taken within the first 24 hours by 23 patients (31.1%) in the low\u2010dose group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.027 versus placebo), 18 patients (34.6%) in the high\u2010dose group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.103 versus placebo), and 29 patients (50.0%) in the placebo group. The low\u2010dose group had an adverse event (AE) profile similar to that of the placebo group, with an odds ratio (OR) of 1.5 (95% confidence interval [95% CI] 0.7\u20133.2). High\u2010dose colchicine was associated with significantly more diarrhea, vomiting, and other AEs compared with low\u2010dose colchicine or placebo. With high\u2010dose colchicine, 40 patients (76.9%) had diarrhea (OR 21.3 [95% CI 7.9\u201356.9]), 10 (19.2%) had severe diarrhea, and 9 (17.3%) had vomiting. With low\u2010dose colchicine, 23.0% of the patients had diarrhea (OR 1.9 [95% CI 0.8\u20134.8]), none had severe diarrhea, and none had vomiting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low\u2010dose colchicine yielded both maximum plasma concentration and early gout flare efficacy comparable with that of high\u2010dose colchicine, with a safety profile indistinguishable from that of placebo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.27327","type":"journal-article","created":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T12:18:53Z","timestamp":1264076333000},"page":"1060-1068","source":"Crossref","is-referenced-by-count":451,"title":["High versus low dosing of oral colchicine for early acute gout flare: Twenty\u2010four\u2013hour outcome of the first multicenter, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group, dose\u2010comparison colchicine study"],"prefix":"10.1002","volume":"62","author":[{"given":"Robert A.","family":"Terkeltaub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Kook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Crockett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1987.tb01232.x"},{"key":"e_1_2_8_3_2","first-page":"545","volume-title":"Current rheumatology and treatment","author":"Hellmann D","year":"2007"},{"issue":"4","key":"e_1_2_8_4_2","first-page":"CD006190","article-title":"Colchicine for acute gout","author":"Schlesinger N","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200013060-00005"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030733"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7426.1275"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_8_11_2","volume-title":"CFR \u2013 Code of Federal Regulations Title 21, Section 312.32","year":"2009"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.08.006"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E197"},{"key":"e_1_2_8_14_2","volume-title":"ACR\/ARHP Annual Scientific Meeting, 2008","author":"Terkeltaub R"},{"key":"e_1_2_8_15_2","first-page":"494","article-title":"Acute colchicine intoxication\u2014possible role of erythromycin administration","volume":"19","author":"Caraco Y","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.SMJ.0000163315.02563.B2"},{"key":"e_1_2_8_17_2","first-page":"181","article-title":"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD): possible role of clarithromycin administration","volume":"55","author":"Dogukan A","year":"2001","journal-title":"Clin Nephrol"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/431592"},{"key":"e_1_2_8_19_2","first-page":"2825","article-title":"Gastrointestinal, hepatorenal, and neuromuscular toxicity caused by cyclosporine\u2010colchicine interaction in renal transplantation","volume":"26","author":"Yussim A","year":"1994","journal-title":"Transplant Proc"},{"key":"e_1_2_8_20_2","volume-title":"Colcrys prescribing information","year":"2009"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.1998.00294.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(03)00065-4"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200309000-00001"},{"key":"e_1_2_8_24_2","unstructured":"Celebrex In Acute Gouty Arthritis Study (NCT00549549). URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00549549?term=NCT00549549&rank=1."},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1488"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20007"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60799-0"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27327","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T09:50:40Z","timestamp":1700733040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1002\/art.27327"],"URL":"https:\/\/doi.org\/10.1002\/art.27327","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.3162961.2851061","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,30]]}}}